| Literature DB >> 23001956 |
Guoxing Zheng1, Shibo Zhong, Yajun Geng, Gnanasekar Munirathinam, Isaac Cha, Catherine Reardon, Godfrey S Getz, Nico van Rooijen, Youmin Kang, Bin Wang, Aoshuang Chen.
Abstract
We previously showed that antigen immunization in the presence of the immunosuppressant dexamethasone (a strategy we termed "suppressed immunization") could tolerize established recall responses of T cells. However, the mechanism by which dexamethasone acts as a tolerogenic adjuvant has remained unclear. In the present study, we show that dexamethasone enriches CD11c(lo) CD40(lo) macrophages in a dose-dependent manner in the spleen and peripheral lymph nodes of mice by depleting all other CD11c(+) CD40(+) cells including dendritic cells. The enriched macrophages display a distinct MHC class II (MHC II)(lo) CD86(hi) phenotype. Upon activation by antigen in vivo, CD11c(lo) CD40(lo) macrophages upregulate IL-10, a classic marker for tolerogenic antigen-presenting cells, and elicit a serum IL-10 response. When presenting antigen in vivo, these cells do not elicit recall responses from memory T cells, but rather stimulate the expansion of antigen-specific regulatory T cells. Moreover, the depletion of CD11c(lo) CD40(lo) macrophages during suppressed immunization diminishes the tolerogenic efficacy of the treatment. These results indicate that dexamethasone acts as a tolerogenic adjuvant partly by enriching the CD11c(lo) CD40(lo) tolerogenic macrophages.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23001956 PMCID: PMC3697049 DOI: 10.1002/eji.201242468
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532